Members of the training class take a group photo in the headquarters of CapitalBio Technology on Aug 15. [Photo provided to chinadaily.com.cn]

A training class consisting of health officials and medical professionals from 11 Belt and Road countries paid a visit to CapitalBio Technology, an industry-leading life science company under Tsinghua Holdings on Aug 15.

The visitors were impressed by the company's independently-developed biochip platform as well as a series of molecular diagnosis products and solutions for urgent clinical needs relating to gene mutations, pathogenic microorganisms and drug resistance.

They gave their thumbs up for the company's outstanding achievements in the prevention, diagnosis and curing of tuberculosis.

The class was organized by the International Exchange and Cooperation Center of NHFPC to deepen ties between China and BRI countries in the health sector, especially with regard to the prevention and treatment of tuberculosis, which has long been a priority of the Chinese government.

According to the National Health Commission, the prevention and control of tuberculosis is part and parcel to China's goal of building a moderately prosperous society and the Healthy China 2030 Initiative.

The Chinese government has built up an inclusive prevention system with all related departments, institutes and enterprises working shoulder to shoulder to prevent tuberculosis all year round.

Chinese institutes and companies, like CapitalBio Technology, have shared their experience and wisdom in tuberculosis control with the world at many international conferences, including the World Health Assembly and the BRICS Health Ministers Meeting. Tuberculosis control is also of great significance to China’s Belt and Road Initiative Disease Control and Prevention project.

Relying on a state-of-the-art biochip platform, CapitalBio is a pioneer in tuberculosis control and developed the fast molecular diagnosis system, China's first turn-key solution covering every aspect of tuberculosis control, including but not limited to screening, identification and chemotherapy.

Registered in 2012 as a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center, CapitalBio Technology has developed into an industry-leading life science company with more than 500 employees, 86 percent of whom have at least a bachelor's degree and 14 percent have a PhD or above.